Nothing said here yet.
to join the conversation.
Ligand Pharmaceuticals (LGND) raised its 2026 adjusted EPS guidance but maintained its royalty and t
Ligand Pharmaceuticals just posted Q3 2026 results, and the story the numbers tell is very different from the mood on the screen.
Royalty revenue surged 51% on XOMA acquisition and Filspari momentum.
Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty.
(AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $28.
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.501; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m.
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference.
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m.
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.
Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs.
Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today.
Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs.